Chordate Medical Holding AB (publ) ("Chordate", the "Company") announces that the European Patent Office intends to grant Chordate's patent application EP 17168265.1 from 2017. The patent application relates to further development of the Company's treatment technology for primarily chronic migraine, Kinetic Oscillation Stimulation, K.O.S.
“The aim of further expanding the patent portfolio is to make it more difficult for a potential competitor to enter our market. The company's intellectual property enables exclusivity in the market, which is a cornerstone of the shareholder value the company is building", says Anders Weilandt, CEO of Chordate Medical.
Chordate Medical holds approximately 71 patents across 26 countries and 9 patent families, covering various aspects of the company's treatment technologies. The granting of application EP 17168265.1 adds further patents to a growing portfolio that the company started to build in 2008.
For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The K.O.S-treatment has clinically proven efficacy according to scientific studies. The company's products are available via distributors to clinics in the Nordic countries, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at chordate.com/en
The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.